Study wrapper · #1323
Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.
Editor's note
The useful contribution is the framing rather than any new data: mechanistic plausibility is not outcome evidence, and this review is explicit about which agents have crossed that line and which have not. As a narrative review with structured literature identification, it carries no pooled estimates and no formal risk-of-bias appraisal, so it should be read as expert synthesis. The lean-mass and discontinuation caveats are the parts most directly relevant to readers following the incretin class outside of a clinic.
Plain-language abstract
A narrative review that sorts incretin drugs by how mature their evidence actually is. The authors draw a line between agents with hard outcome data — real reductions in cardiovascular events or kidney decline, with semaglutide singled out for its dedicated kidney evidence — and the newer dual, triple, amylin-linked, and oral agents, which so far rest mainly on blood sugar, weight, and early laboratory endpoints. Their argument is that which agent suits a given patient should follow that evidence hierarchy and the patient's own profile, not the appeal of the mechanism. They also flag the boundaries that still apply: gut tolerability, lean-mass loss, durability, and what happens on discontinuation.